Johnson Matthey PLC (LON:JMAT - Get Free Report) shares crossed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of GBX 1,391.54 ($18.88) and traded as high as GBX 1,694 ($22.99). Johnson Matthey shares last traded at GBX 1,694 ($22.99), with a volume of 444,720 shares traded.
Johnson Matthey Price Performance
The company's fifty day moving average is GBX 1,425.34 and its 200 day moving average is GBX 1,399.34. The firm has a market cap of £2.85 billion, a price-to-earnings ratio of 28.97, a PEG ratio of 49,242.50 and a beta of 0.95. The company has a quick ratio of 0.76, a current ratio of 1.45 and a debt-to-equity ratio of 62.73.
Johnson Matthey (LON:JMAT - Get Free Report) last issued its quarterly earnings data on Thursday, May 22nd. The company reported GBX 149.20 ($2.02) earnings per share for the quarter. Johnson Matthey had a net margin of 0.84% and a return on equity of 4.49%. On average, equities research analysts predict that Johnson Matthey PLC will post 173.4112903 EPS for the current year.
Johnson Matthey Increases Dividend
The firm also recently declared a dividend, which was paid on Wednesday, April 16th. Investors of record on Thursday, April 10th were given a dividend of GBX 32 ($0.43) per share. This represents a yield of 1.88%. This is a positive change from Johnson Matthey's previous dividend of $22.00. The ex-dividend date was Thursday, April 10th. Johnson Matthey's dividend payout ratio (DPR) is currently 130.84%.
Insider Buying and Selling
In related news, insider Liam Condon purchased 30 shares of the firm's stock in a transaction that occurred on Wednesday, April 16th. The shares were bought at an average cost of GBX 1,200 ($16.28) per share, with a total value of £360 ($488.47). Over the last three months, insiders have acquired 75 shares of company stock valued at $99,927. 0.61% of the stock is owned by company insiders.
Johnson Matthey Company Profile
(
Get Free Report)
Johnson Matthey is a global leader in science that enables a cleaner and healthier world. With over 200 years of sustained commitment to innovation and technological breakthroughs, they improve the function, performance and safety of their customers' products. Their science has a global impact in areas such as low emission transport, pharmaceuticals, chemical processing and making the most efficient use of the planet's natural resources.
Featured Articles
Before you consider Johnson Matthey, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson Matthey wasn't on the list.
While Johnson Matthey currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
